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ABSTRACT 
 
A simple, selective, rapid, precise and economical reverse phase high performance liquid chromatographic 
method has been developed for the simultaneous estimation of meclizine hydrochloride and nicotinic Acid from 
pharmaceutical formulation using C18 (25 cm x 4.6 mm i.d., 5 ?) column with a mobile phase consisting of 
Methanol: water (adjusted to pH 3.0 using orthophosphoric acid) in the ratio of 80:20 v/v. The detection 
wavelength was carried out at 231 nm.  The linear regression analysis data for the linearity plot showed good 
linear relationship with correlation coefficient value for Meclizine Hydrochloride and Nicotinic Acid were 
R2=0.9991 and R2=0.9996 in the concentration range of 10-70 ?g/ml, 5-35 ?g/ml respectively. The validation of 
method was carried out utilizing ICH-guidelines. The proposed method can be used for the estimation of these 
drugs in combined dosage forms. 
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INTRODUCTION 
Meclizine Hydrochloride [MEC] (Figure 1), chemically 1-(p-chloro-alpha-phenyl, benzyl)- 4- (m-methyl-
benzyl)-piperazine dihydro chloride monohydrate. It is an antihistamine, considered to be antiemetic it is used as 
an anti vertigo or antiemetic agent, specifically in the prevention and treatment of nausea, vomiting and 
dizziness associate with motion sickness. It works by blocking a chemical messenger in the brain, it helps to 
reduce or prevent vomiting and dizziness caused by motion sickness. It also used for vertigo caused by certain 
inner ear problems. Meclizine should be taken with caution in the elderly because of increased risk of confusion 
and amnesia. The drug is safe in pregnancy. Figure 1. 
Nicotinic acid [NA] (pyridine-3-carboxylic acid) is a B group vitamin. It is one of the oldest known agent for 
the treatment of dyslipidemia. It favorably modifies the major lipid and lipoprotein classes that are recognized as 
independent risk factors for atherosclerosis and coronary heart disease. It can be used as a therapeutic option for 
cardiovascular risk reduction in atherogenic dyslipidemia. Chronic administration of Nicotinic acid reduces 
whole body insulin sensitivity via elevation of circulating fatty acid and accumulation of skeletal muscle lipid. 
Nicotinic acid and its derivatives can be used as peripheral vasodilators. Figure 2. 
Several analytical methods based on UV 1, Spectroflourimetry 9, RP-HPLC 3-5, HPTLC 2, Electrophoresis 7-8 and 
LC-MS 6 was reported for the determination of metformin. Although literature survey reveals that various 
methods were reported for Meclizine hydrochloride and Nicotinic Acid both for single estimation and in 
combination with others drugs, but no estimation method has been reported for the analysis of these drugs in 
combination. 












Fig. 2 Nicotinic Acid 
 
EXPERIMENTAL 
HPLC instrumentation and conditions 
HPLC system (Agilent HPLC Model-1200 with Ezchromeelite Software) containing C18 (Agilent, 250 x 4.6 
mm. 5 µ) column with UV- PDA detection. LABINDIA-3000+ UV-Visible double beam spectrophotometer 
with a fixed slit width 1nm and 1cm matched quartz cells was used for all the spectral measurements. 
Chemicals and reagents 
Analytically pure MEC and NA were kindly provided by Hetero Labs Ltd, Hyderabad as gift samples. 
Analytical grade methanol was purchased from Merck & Co. Glassware’s used in each procedure were soaked 
overnight in a mixture of chromic acid and sulphuric acid rinsed thoroughly with double distilled water and 
dried in hot air oven. Water (HPLC grade) was purchased from Merck, India. Triple distilled water is used for 
all purpose. 
Chromatographic conditions 
The mobile phase consisted of Methanol and water in ratio Methanol: Water (80:20), and pH was adjusted to 3.0 
with OPA. The contents of the mobile phase were filtered before use through a 0.45? membrane and degassed 
for 10 min. The mobile phase was pumped from the solvent reservoir to the column at a flow rate of 1.0 ml/ min 
and the injection volume was 20 ?l. The column temperature was maintained at ambient temperature. The 
eluents were monitored at 231 nm. The result of the optimized chromatogram was shown in Figure3 and Table1.   
Preparation of standard stock solutions 
Accurately weighed 10 mg of MEC and NA standard were transferred to separate 10 ml volumetric flask and 
dissolved in 10 ml Methanol. The flasks were shaken and volume was made up to the mark with Methanol to 
give solutions containing 1000 ?g/ml MEC and 1000 ?g/ml NA. From this solution 1ml was transferred to 
volumetric flask of 100 ml capacity. Volume was made up to the mark to give a solution containing 100 ?g/ml 
MEC and 100 ?g/ ml NA. 
Calibration of standards 
The standard calibration curve was constructed for Nicotinic Acid and Meclizine Hydrochloride. Different 
volumes of stock solutions of each were accurately transferred in to 10 ml volumetric flasks and diluted to mark 
to yield a concentration range of 5-35 ?g/ml solutions of Nicotinic Acid and 10-70 ?g/ml solutions of Meclizine 
hydrochloride. The calibration line was obtained by plotting the peak area against concentration of drug.  
Sample preparation 
Twenty tablets of marketed formulation PNV tab (Yash Pharma, Mumbai, India) containing MEC 25 mg and 
NA 50 mg formulation were weighed, and finely powdered. Tablet powder equivalent to 100 mg PIO with 




relevant quantities of MET was weighed and transferred to a 100 ml volumetric flask, extracted for 30mins with 
water and volume was made up to 100 ml with diluent. 0.25 ml of above solution was taken in 10 ml volumetric 
flask  and  volume  was  made  up  to  10  ml  with  mobile  phase,  and  final  solution  was  filtered  through  0.45  µ  
syringe filter and it was analysed. The results of the assay were shown in Table 4. 
Method validation 
The proposed method has been extensively validated in terms of specificity, linearity, accuracy, precision, limits 
of detection (LOD) and quantification (LOQ), robustness and reproducibility. The accuracy was expressed in 
terms of percent recovery of the known amount of the standard drugs added to the known amount of the 
pharmaceutical dosage forms. The precision (Coefficient of Variation - C.V.) was expressed with respect to the 
repeatability, intra-day and inter-day variation in the expected drug concentrations. After validation, the 
developed methods have been applied to pharmaceutical dosage form. 
 
System Suitability Criteria  
It is defined as tests to measure the method that can generate result of acceptable accuracy and precision. The 
system suitability was carried out after the method development and validation have been completed. The 
system suitability was assessed by five replicate analyses of the drugs at concentrations of 20 ?g/ml of MEC and 
30 ?g/ml of NA and for this, parameters like plate number (n), tailing factor, HETP, peak asymmetry of samples 
were measured, and shown in table 2. 
RESULTS 
Method Validation parameters 
Method was validated as per ICH (Q2) guidelines with respect to linearity, accuracy, precision, specificity, and 
robustness, limit of detection and limit of quantification. 
a)  Specificity 
Commonly used excipients (starch, microcrystalline cellulose and magnesium stearate) were spiked into a pre 
weighed quantity of drugs. Specificity of the method was shown by quantifying the analyte of interest in the 
presence of matrix and other components. Blank injections have shown no peaks at retention time of 3.3 min 
and 5.5 min, the proposed method was specific for the detection of NA and MEC respectively. The selectivity of 
the method was performed by injecting the solution after the degradation. The degradants formed during 
solution stability study were well separated from the analyte peak after 20 hrs of sample preparations. Thus the 
method can be applied to evaluate the stability of the solution. 
b) Linearity 
Appropriate volume of aliquot from NA and MEC standard stock solution was transferred to volumetric flask of 
10 ml capacity. The volume was adjusted to the mark with methanol to give a solution containing 5-30 ?g/ml 
NA and 10-70 ?g/ml MEC. The slope, Y-intercept and correlation coefficient were calculated. The regression 
line relating standard concentrations of drug using regression analysis, the calibration curves were linear in the 
studied range and equations of the regression analysis were obtained: Y=143611x+63798; R2=0.9996 for NA 
and Y=92198x+13890; R2=0.9991 for MEC respectively. The mean and correlation coefficient of standard 
curves (n=3) were calculated. The represented data was shown in below figure 4,6 and Table 3. 
c)  Accuracy 
Accuracy was assessed by determination of the recovery of the method by addition of standard drug to the pre-
quantified placebo preparation at 3 different concentration levels 80%, 100% and 120%, taking into 
consideration percentage purity of added bulk drug samples. Each concentration was analyzed 3 times and 
average recoveries were measured. Results of assay and recovery were presented in the table 5. 
d) Precision 
The repeatability was evaluated by assaying 6 times of sample solution prepared for assay determination. The 
intraday and interday precision study of MEC and NA was carried out by estimating same concentration of NA 
(20 ?g./ml) and MEC (30 ?g/ml), 6 times on the same day and on 3 different days (first, second, third) and the 
results are reported in terms of C.V. The results are shown in Table VIa and VIb .Table 6.  
e) Robustness  




The robustness of the method was evaluated by analyzing the system suitability standards and evaluating system 
suitability parameter data after varying the HPLC pump flow rate (±0.1 ml) and organic solvent content (±2ml) 
and Wavelength(±0.2) .The alterations caused a significant change in peak area R.S.D (%), USP tailing factor 
and retention times. Results of robustness studies are shown in Table 7. 
f) LOD and LOQ 
LOD and LOQ were calculated from the formula 3.3 x (?/S) and 10 x (?/S), respectively where, ? is standard 
deviation of intercept and S is the mean of slope. The LOD and LOQ can also be determined by S/N. The value 
for LOD should be 3-5 whilst for LOQ 10-15. The results are presented in Table 8.  
g) Solution stability and Mobile phase stability  
The stability of NA and MEC in solution was determined by leaving test solutions of the sample and reference 
standard in tightly capped volumetric flasks at room temperature for 3 days during which they were assayed at 
12 hr intervals. Stability of mobile phase was determined by analysis of freshly prepared sample solutions at 12 
hr intervals for 48 hrs and comparing the results with those obtained from freshly prepared reference standard 
solutions. The mobile phase was prepared at the beginning of the study period and not changed during the 









1 Mobile Phase 
Optimized 
80 MeOH : 20 H2O 0.2%TEA, pH 3.0 
adj., with OPA  
2 Flow Rate (mL/ min) 1 
3 Run Time (min) 10 
4 Column Temperature 
OC 
23 
5 Volume of Injection 
??L) 
20 
6 Detection Wavelength 
(nm) 
231 
7 Retention time Rt NA -3.3 min, MEC-5.5min 
 
 
Table 2: System suitability parameters for Meclizine Hydrochloride and Nicotinic Acid 
Parameter Values obtained (n = 6) Acceptance Criteria 
Nicotinic Acid Meclizine Hydrochloride 
Plate Count 9871 ± 62 6019 ± 87 >4000 
Tailing Factor 1.094 ± 0.018 1.582 ± 0.022 ? 2.0 
Capacity factor 0.64 2.24               0.5<k<20 
HETP 0.00253 0.00415 ---- 




Table 3: Calibration of Meclizine Hydrochloride and Nicotinic Acid 
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Peak Area mean± 
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514042 ± 4112 
925385 ± 1388 
1383993 ± 6919 
1833394 ± 20167 
2299671 ± 29895 
2760404 ± 19322 




















Table 4: Assay report of formulation 
S. No. Brand name Content Peak Area mean ± S.D Assay % RSD 
1 PVB 20mg-Nicotinic Acid 2818764 ±38450  100.35% 1.3641 
  40mg-Meclizine HCl     1833394 ± 16817 98.67% 0.9173 
 
 






















35.38 ± 0.462 
40.23 ± 0.351 
















71.84 ± 0.851 
80.17 ± 1.156 








Table 6: Precision 
 Intra-day and Inter-day Precision 






























































































































Table 7: Robustness studies of Meclizine Hydrochloride and Nicotinic Acid 
S. No Parameter Modification Retention time          Asymmetry 







0.9 mL/ min 
1.0 mL/ min 
1.1 mL/ min 





















78 : 22 
80 : 20 










































Table 8: LOD and LOQ data 
S.No Parameter  NA MEC 
1 LOD(µg/ml) 0.025  0.299  
2 LOQ(µg/ml) 0.083   0.909 
 
























The proposed method gave good resolution between MEC and NA within short analysis time (10 min).  
Solution stability studies showed that the active pharmaceutical ingredients remained stable for 24 hrs at room 
temperature. The changes in flow rate, Wavelength, composition of mobile phase affected the retention times of 
the drugs, confirming that the method is not robust for change in Wavelength and mobile phase composition. 
High percentage recovery of drug shows the method is free from interference of excipients present in the 
formulation. Thus the proposed method is simple, rapid, sensitive, specific, accurate, and precise and does not 
involve complicated sample preparation procedures. The use of C18 column in the present work has shown better 
elution of analytes with good resolution, improved plate count, capacity factor. So the C18 column can be used to 
achieve high specificity in shorter time of analysis of Meclizine Hydrochloride and Nicotinic Acid as per ICH 
Q2 (R2) guidelines.  
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